Researchers from USask have identified a potential target for eliminating breast cancer cells. The team was led by Dr. Franco Vizeacoumar (Ph.D.) and Dr. Andrew Freywald (Ph.D.) with USask and the ...

Detailed price information for Cyclacel Pharmaceuti (CYCC-Q) from The Globe and Mail including charting and trades.

We reasoned there could be another kinase that would be a better target and that’s how we found PLK1.” PLK1 inhibition, the researchers wrote in Gut, “had the most pronounced effect on FLC cells” ...

announced it will present data from AP3 Generative Phosphoproteomic analyses of ACR-2316-regulated CDK1-, CDK2-, and PLK1-induced pathways at the American Association for Cancer Research (AACR ...

Results Functional screening, coupled with computational analysis, highlighted Polo-like kinase 1 (PLK1) as vital for FLC cell viability. Genetic and pharmacological PLK1 inhibition significantly ...

SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of ...

SAN DIEGO, April 15, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of ...

In this study, researchers found that the molecule PLK1 promotes the degradation of PDCD4, causing the activation of a pathway that clears some drugs and promotes proliferation. "These results ...

Peer ReviewDownload a summary of the editorial decision process including editorial decision letters, reviewer comments and author responses to feedback. Polo-like kinase 1 (PLK1) is a conserved ...

Cardiff Oncology’s investigational PLK1 inhibitor paired with standard-of-care treatment showed a 64% overall response rate (ORR) in the high-dose cohort of a midstage colorectal cancer trial.

In this study, we referred to the co-crystal complex of PLK1 and PCM075 (2YAC) and utilized the RiDYMO platform's comprehensive capabilities to synthesize and test under 100 compounds, leading to the ...

Notable's main focus has been volasertib, a polo-like kinase 1 (PLK1) inhibitor licensed from Boehringer three years ago that was being lined up for a phase 2 study in acute myeloid leukemia.